Biostatistics Core

C O R E D： 生物统计核心的工作人员将负责为相关研究提供生物统计支持。 治疗反应和复发率。生物统计核心由以下人员监督： 博士Timothy D.密歇根大学公共卫生学院生物统计学系的约翰逊说。 核心提供协助的设计，分析和解释的临床前和临床实验 的项目。核心人员将与项目调查人员互动，以确保适当的 使用设计和分析方法。设计问题涉及剂量选择、随机化、给药时间 测量值、动物或患者的数量。对于数据分析，核心将确保高效 方法被使用。将使用标准的图形、组比较和相关分析方法 对实验数据进行初步调查。混合模型方法将用于有效利用 重复测量的实验数据。核心人员在设计方面经验丰富， 分析动物和临床数据。这将确保有效收集所有数据， 适当分析。尽管这些任务与Core C中描述的任务不同，但 将保持核心D和C之间的数据流，以便可以分析重叠实验的数据分析 以有效和富有成效的方式。同样，岩心B将作为大部分成像数据的来源 使用统计建模进行后续分析，因此与该核心的密切互动也将是关键， 该计划的成功。 相关性（参见说明）： 总的来说，该核心将为确定新的分子生物学组合的疗效提供基础。 用于治疗恶性脑肿瘤的靶向疗法。此外，成像生物标志物的早期 将确定和验证治疗反应评估，这将导致个体化 耐心治疗。

C O R E D : The staff of the Biostastics Core will be responsible for providing biostatistical support to the research related to therapeutic response and recurrence of this program. The Biostatistical Core is under the supervision of Dr. Timothy D. Johnson of the Biostatistics Department in the University of Michigan School of Public Health. The core provides assistance in the design, analysis and interpretation of preclinical and clinical experiments of the program project. Core personnel will interact with project investigators to ensure that appropriate designs and methods of analysis are used. Design issues involve selection of dose, randomization, timing of measurements, number of animals or patients. For analysis of data, the core will ensure that efficient methods are used. Standard graphical, group comparison and correlation methods of analysis will be used for initial investigation of the experimental data. Mixed model methods will be used for efficient use of the data in experiments involving repeated measures. Core personnel are experienced in the design and analysis of both animal and clinical data. This will ensure that all data will be collected efficiently and analyzed appropriately. Although these tasks are distinct from thise described in Core C, a close interaction between Cores D and C will be maintained so that data analysis of overiapping experiments can be analyzed in an efficient and productive manner. Similarly Core B will serve as a source of a majority of imaging data for subsequent analysis using statistical modeling and thus close interaction with this Core will also be key to the success of the program. RELEVANCE (See instructions): Overall, this Core will provide the basis for determining the efficacy of new combinations of moleculariy targeted therapies for the treatment of malignant brain tumors. In addition, imaging biomarkers for early assessment of treatment response will be identified and validated which will lead to individualization of patient treatment.